Cipla : JP Morgan Healthcare Conference

JP Morgan Healthcare Conference

Umang Vohra, MD & Global CEO

January 2022

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward- looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

2

Established in 1935, Cipla has transformed into a world class pharmaceutical company with formidable branded and unbranded generic market franchise on the back of deep-rooted R&D capabilities and strong execution

Our relentless focus of bringing in best-in-class drugs resonates with our purpose of

'Caring for Life'; serving patients via innovative respiratory drug-device combinations, complex

formulations and broad-spectrum capabilities in injectables, oral solids and inhalation amongst others

One-India	South Africa	North America	International
Markets

3rd	3rd	8th	2nd
Largest	Largest pharma	Largest by	Largest Indian
pharma	company in the	prescriptions	exporter to EMs4
company	prescription and	in the US3
in India1,2	OTC1 space

1. As per IQVIA MAT Nov'21; 2. Including branded prescription, trade generics and consumer health business; 3. Market share among generic players as per IQVIA	3
week ending 24th December 2021 4. As per EXIM data for APAC, LATAM, ANZ and MENA Oct'20 - Sept'21

In FY22, we delivered strong progress on our strategic priorities for FY25 (1/2)

FY25 targets		YTD FY22 progress

Expanding lung leadership globally and

maximising value opportunity in US complex generics

Maintain market-beating growth in large branded and unbranded generic franchises of India & South Africa; augment consumer wellness franchise

Focused DTMs1 and new frontier markets (China

• Brazil) for organic growth in Europe and Emerging markets; expanding biosimilar partnerships in key markets

Incremental

opportunity to add $300Mn-$500Mn by FY25

Market-beating growth in India & South Africa and 10% share of consumer business

Drive sustainable growth through organic

and inorganic levers

Launch & scale-up in

respiratory assets

Albuterol & Arfomoterol; Peptide portfolio unlocking

Continued market beating performance in India & SA; share of consumer business 7%+

Tracking annualized revenue

of $400Mn+

1. DTM - Direct to market

4

In FY22, we delivered strong progress on our strategic priorities for FY25 (2/2)

FY25 targets		YTD FY22 progress

Leverage digital capabilities to deliver

transformative business and patient outcomes in the new normal

Focus on regulatory compliance across

manufacturing locations and embrace best-in class globally benchmarked ESG1 practices

Digital patient	Continued rigor on
creating industry leading
care continuum
digital initiatives

Global benchmark for	Inclusion in Dow Jones
quality compliance &	Sustainability Emerging
ESG	Markets Index

	Consistent upward RoIC2 trajectory over the	RoIC expansion to 17%-	Trailing 12-month (Sept-
	long term	20% over the long term	21) RoIC at 22.0%

1. Environmental, Social, Governance 2. Return on Invested Capital (RoIC) = EBITDA - depreciation & amortization ÷ Average [(Fixed assets including goodwill +	5
Current assets excluding cash and cash equivalent) - Current liabilities excluding borrowing)]; H1FY21: Calculations based on Trailing 12-month EBITDA